Sagimet Biosciences (SGMT) Competitors $5.05 -0.05 (-0.98%) (As of 12/9/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SGMT vs. ABUS, TRML, TSHA, ESPR, STOK, GLUE, EXAI, PHVS, IGMS, and SANAShould you be buying Sagimet Biosciences stock or one of its competitors? The main competitors of Sagimet Biosciences include Arbutus Biopharma (ABUS), Tourmaline Bio (TRML), Taysha Gene Therapies (TSHA), Esperion Therapeutics (ESPR), Stoke Therapeutics (STOK), Monte Rosa Therapeutics (GLUE), Exscientia (EXAI), Pharvaris (PHVS), IGM Biosciences (IGMS), and Sana Biotechnology (SANA). These companies are all part of the "pharmaceutical products" industry. Sagimet Biosciences vs. Arbutus Biopharma Tourmaline Bio Taysha Gene Therapies Esperion Therapeutics Stoke Therapeutics Monte Rosa Therapeutics Exscientia Pharvaris IGM Biosciences Sana Biotechnology Sagimet Biosciences (NASDAQ:SGMT) and Arbutus Biopharma (NASDAQ:ABUS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, community ranking, dividends and analyst recommendations. Is SGMT or ABUS more profitable? Sagimet Biosciences has a net margin of 0.00% compared to Arbutus Biopharma's net margin of -1,137.65%. Sagimet Biosciences' return on equity of -23.63% beat Arbutus Biopharma's return on equity.Company Net Margins Return on Equity Return on Assets Sagimet BiosciencesN/A -23.63% -22.91% Arbutus Biopharma -1,137.65%-68.18%-51.55% Does the MarketBeat Community prefer SGMT or ABUS? Arbutus Biopharma received 408 more outperform votes than Sagimet Biosciences when rated by MarketBeat users. However, 96.30% of users gave Sagimet Biosciences an outperform vote while only 71.03% of users gave Arbutus Biopharma an outperform vote. CompanyUnderperformOutperformSagimet BiosciencesOutperform Votes2696.30% Underperform Votes13.70%Arbutus BiopharmaOutperform Votes43471.03% Underperform Votes17728.97% Do institutionals and insiders believe in SGMT or ABUS? 87.9% of Sagimet Biosciences shares are held by institutional investors. Comparatively, 43.8% of Arbutus Biopharma shares are held by institutional investors. 17.6% of Sagimet Biosciences shares are held by company insiders. Comparatively, 4.0% of Arbutus Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has better earnings & valuation, SGMT or ABUS? Sagimet Biosciences has higher earnings, but lower revenue than Arbutus Biopharma. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSagimet Biosciences$2M79.14-$27.88MN/AN/AArbutus Biopharma$18.14M38.65-$72.85M-$0.43-8.60 Does the media prefer SGMT or ABUS? In the previous week, Sagimet Biosciences had 3 more articles in the media than Arbutus Biopharma. MarketBeat recorded 7 mentions for Sagimet Biosciences and 4 mentions for Arbutus Biopharma. Arbutus Biopharma's average media sentiment score of 0.38 beat Sagimet Biosciences' score of 0.11 indicating that Arbutus Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sagimet Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arbutus Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts recommend SGMT or ABUS? Sagimet Biosciences currently has a consensus price target of $23.00, indicating a potential upside of 345.74%. Arbutus Biopharma has a consensus price target of $5.50, indicating a potential upside of 48.65%. Given Sagimet Biosciences' higher probable upside, analysts plainly believe Sagimet Biosciences is more favorable than Arbutus Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sagimet Biosciences 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.86Arbutus Biopharma 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, SGMT or ABUS? Sagimet Biosciences has a beta of 2.3, meaning that its stock price is 130% more volatile than the S&P 500. Comparatively, Arbutus Biopharma has a beta of 1.84, meaning that its stock price is 84% more volatile than the S&P 500. SummarySagimet Biosciences beats Arbutus Biopharma on 12 of the 16 factors compared between the two stocks. Ad DTIWhy I'm telling friends to avoid gold stocksBack in November, gold made a tiny move of 1.6%. But according to my backtesting by using a special type of gold trade, I would have seen a 141% gain in just a week. It happened again in March. Gold nudged up 1.2%. This time? A 104% overnight gain. And in June? A 1% gold move turned into a 74% gain in two weeks. Granted, there would have been smaller wins and those that did not work out, but you see, there's a reason I'm telling all my friends to hold off from buying gold or regular gold stocks right now. There's a more lucrative way to play the gold market as we enter a new breakout period. It's all about catching what I call "Acceleration Cycles."And if you’d like to get your hands on this, here you go, the complete breakdown. Get Sagimet Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for SGMT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SGMT vs. The Competition Export to ExcelMetricSagimet BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$158.28M$6.58B$5.07B$9.19BDividend YieldN/A8.10%7.71%4.06%P/E RatioN/A5.0178.9413.80Price / Sales79.14349.151,404.51160.86Price / CashN/A22.4934.4735.60Price / Book1.305.454.824.99Net Income-$27.88M$149.04M$115.32M$223.34M7 Day Performance-3.73%1.01%3.63%1.64%1 Month Performance-13.13%-2.48%119.50%7.24%1 Year Performance42.15%25.26%157.29%30.71% Sagimet Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SGMTSagimet Biosciences2.0678 of 5 stars$5.05-1.0%$23.00+355.4%+40.5%$154.91M$2M0.008Analyst ForecastABUSArbutus Biopharma2.6673 of 5 stars$3.50+1.2%$5.50+57.1%+77.8%$663.22M$18.14M-8.0573TRMLTourmaline Bio2.3844 of 5 stars$25.46-2.2%$65.00+155.3%+39.3%$652.79MN/A-9.1344Analyst ForecastNews CoveragePositive NewsTSHATaysha Gene Therapies3.9273 of 5 stars$3.17-2.2%$6.63+109.0%N/A$649.67M$9.92M5.14180ESPREsperion Therapeutics3.9503 of 5 stars$3.25+16.1%$8.17+151.3%+133.6%$640.38M$116.33M-4.64240STOKStoke Therapeutics3.8219 of 5 stars$12.08-0.2%$20.83+72.5%+178.2%$639.88M$8.78M-5.77100GLUEMonte Rosa Therapeutics2.3983 of 5 stars$10.35-0.1%$16.00+54.6%+117.3%$635.87M$14.98M-5.7190EXAIExscientia2.5999 of 5 stars$4.84+3.2%$7.00+44.6%-13.3%$632.93M$25.60M-3.21280Positive NewsHigh Trading VolumePHVSPharvaris1.9375 of 5 stars$19.67-10.2%$33.60+70.8%-25.0%$626.29MN/A-6.9830Gap DownIGMSIGM Biosciences4.7074 of 5 stars$10.53+4.9%$16.13+53.1%+55.0%$626.16M$2.92M-2.76190Analyst ForecastSANASana Biotechnology2.691 of 5 stars$2.75-1.1%$13.50+390.9%-38.2%$613.99MN/A-1.91328 Related Companies and Tools Related Companies Arbutus Biopharma Competitors Tourmaline Bio Competitors Taysha Gene Therapies Competitors Esperion Therapeutics Competitors Stoke Therapeutics Competitors Monte Rosa Therapeutics Competitors Exscientia Competitors Pharvaris Competitors IGM Biosciences Competitors Sana Biotechnology Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SGMT) was last updated on 12/9/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredThe Crypto Secret Wall Street Doesn’t Want You to KnowThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredWaveBot: The Automated Trading Tool for This Bull MarketThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | Sponsored⭕ [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sagimet Biosciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sagimet Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SGMT Stock Alerts